A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Starting soon · Phase 1
Conditions studied: Melanoma
In brief
This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL\_PB (proposed Keytruda® biosimilar) versus Keytruda (pembrolizumab) when administered as monotherapy in participants with fully resected Stage IIB/C or Stage III melanoma requiring adjuvant treatment with pembrolizumab. Eligible participants will be randomized in a 1:1 ratio to the AVT32-DRL\_PB or Keytruda treatment group and stratified by sex (female versus male) and body weight category (≤75 kg versus \>75 kg). Study treatments will be administered every 3 weeks (Q3W) as an intravenous (IV) infusion over 30 minutes (1 administration Q3W is 1 treatment cycle). The administered pembrolizumab dose will be 200 mg Q3W for both treatment groups.
Key facts
- Study ID
- NCT07475572
- Run by
- Alvotech Swiss AG
- People needed
- 120
- Starts
- 2026-06-19
- Expected to finish
- 2028-04-14
- Last updated by the study team
- 2026-03-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants (male/female) ≥18 years of age at the time of signing the ICF.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at the time of enrollment.
- Participants with Stage IIB, IIC, or III histologically confirmed cutaneous melanoma
You may not qualify if…
- Have had a solid organ transplant or bone marrow (stem cell) transplant that used donor stem cells (allogenic).
- Has received prior systemic anticancer therapy for melanoma including investigational agents.
- Participants with a history of mucosal or uveal melanoma, even if diagnosis and treatment were completed >5 years ago.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.